Kettering Health brought new access to specialized testing through Abbott’s cardiovascular system, helping patients get evaluated for a condition that can be difficult to detect. The system serves patients with Coronary Microvascular Dysfunction (CMD), a heart condition that prevents the tiny blood vessels branching off the main coronary arteries from widening properly, which reduces blood flow to the heart muscle. Previously, patients may have had to travel farther to access this type of testing. Now Kettering Health offers it locally, making it easier for patients to be evaluated for CMD and receive appropriate treatment. The 30-minute procedure allows physicians to assess these smaller blood vessels that may not be evaluated during a traditional heart catheterization. Dr. Damian Valencia, FACC, FSCAI, Dr. Abdur Rehman and the entire catheterization lab team led the first procedure in early 2026 using Abbott’s PressureWire™ X Guidewire and CoroFlow‡ Cardiovascular System at Kettering Health’s Soin Medical Center.

Why We Did It

CMD is a common condition that can be difficult to detect and can increase the risk of heart attack and heart failure. Patients with CMD may experience chest pain and shortness of breath without an obvious cause. In fact, an estimated 50% to 65% of patients with chest pain may have small-vessel heart problems. A 2021 study published in the Cleveland Clinic Journal of Medicine notes that CMD affects an estimated 3 to 4 million people in the U.S. 

This new technology gives physicians a way to assess these smaller blood vessels and more precisely identify CMD when traditional testing does not clearly explain a patient’s symptoms. By looking at the heart’s smallest blood vessels, the system can help physicians more quickly determine the appropriate care.


Community Voice

“If you think of the coronary arteries like a tree, we only look at the tree trunk and the main branches when we do a heart cath. In reality, that tree has thousands of branches.”
Dr. Damian Valencia
Cardiologist